Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy
about
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Neoadjuvant therapy in the treatment of breast cancerNeoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancerEvaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.Landscape of neoadjuvant therapy for breast cancerFirst-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis.Classical pathology and mutational load of breast cancer - integration of two worlds.Current approaches for neoadjuvant chemotherapy in breast cancer.A novel staging model to classify oesophageal squamous cell carcinoma patients in China.Surgical considerations in patients receiving neoadjuvant systemic therapy.Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.Modern therapies and iatrogenic changes in breast pathology.Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis.Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.Early Surrogate Markers of Treatment Activity: Where Are We Now?Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be.Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
P2860
Q27304609-958C9750-0E26-437C-A8A4-B54FCE281ECCQ27694514-F270D766-9BCE-48F8-B43C-52ED0367745CQ30588206-49ED90DD-4DE5-483C-B74E-96036162A3A8Q34572215-1E6C1705-E600-4C49-899D-864B846B250AQ35215035-90C32ED9-2C1A-47BF-B1FD-7BC447C6BF77Q35609695-FC6B10D4-C026-4878-8C44-1E691ECAE146Q35620241-6EA0A32E-9C59-4FD4-AEEF-FAB5EF3966E3Q35794915-22977B8D-25F9-429B-848C-82FE9A5FB2D6Q35896455-93F152CD-81A0-4A36-81C4-D1055DA8BE65Q36359020-3751A18B-A7B9-42D8-AD1E-C0765D2040A1Q37082568-4792075D-8315-402B-A8AE-6FF75633EA09Q37135365-F5C7E1A3-8614-4954-B5AC-26781EBD081BQ37711626-65BD01E8-1094-4318-9CCE-FBFD1DC40BBDQ37992692-754006D4-2A6D-4F8B-86CC-8A5EAF367A8DQ38451966-BE3863E5-8678-4D4E-8A2A-47FC6092BA2AQ38778259-E1BBEC61-811A-4E3A-B2FC-C1B79CB7C4A5Q38886900-FC69EB25-7563-403D-9419-7DABE66D5487Q39037636-B0B85956-8978-4D7F-8598-BF40B653E425Q39109484-530EF5DD-6552-4340-AF51-3F5288B8ACC6Q39666322-CE63FBB4-38AB-4AE3-BE68-79F224CB29AEQ40239249-0EC0CBA2-5D91-4006-88A8-6A9C6A27F5B6Q40382522-75E9F0B4-CB3B-4F32-ACEB-17766CD935E4Q41483585-35814DCB-1C3C-4410-86E4-7EAF21BA670DQ45134639-22B41723-6FC6-4F12-A169-B940B282529DQ49035643-601437A9-3417-418A-B94B-1F48EAB507F3Q51675792-3670E632-18C5-41D2-8E2D-826439BA6FBDQ55056778-570A2DFD-429C-444D-800D-5E8776732BA2Q57192072-D4778A1F-DA13-4B6F-8975-C6E45F335040
P2860
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Validation of a novel staging ...... with neoadjuvant chemotherapy
@ast
Validation of a novel staging ...... with neoadjuvant chemotherapy
@en
type
label
Validation of a novel staging ...... with neoadjuvant chemotherapy
@ast
Validation of a novel staging ...... with neoadjuvant chemotherapy
@en
prefLabel
Validation of a novel staging ...... with neoadjuvant chemotherapy
@ast
Validation of a novel staging ...... with neoadjuvant chemotherapy
@en
P2093
P2860
P356
P1476
Validation of a novel staging ...... with neoadjuvant chemotherapy
@en
P2093
Aman U Buzdar
Ana M Gonzalez-Angulo
Aparna Kolli
Aysegul A Sahin
Elizabeth A Mittendorf
Gabriel N Hortobagyi
Jacqueline S Jeruss
Janice N Cormier
Kelly K Hunt
Lisa A Newman
P2860
P304
P356
10.1200/JCO.2010.31.8469
P407
P577
2011-04-11T00:00:00Z